Participant flow
A total of 346 participants who completed eligibility screening between February 2019 and March 2020, were randomised to VP or PV sequence (173 each). Of these, valid HbA1c data were obtained in 261 participants after vildagliptin and 237 participants after pioglitazone, with 203 participants completing both assessments (Flow diagram of the study participants included in this analysis.